Drug Information Journal, Vol. 24, pp. V–XII, 1990
Printed in the USA. All rights reserved.

0092-8615/90 $3.00 + .00
Copyright © 1990 Drug Information Association Inc.

Contents
Volume 24, 1990

Volume 24, Number 1 1990

CONTENTS

Rx-to-OTC Switch

R. William Soller	1	Introduction
William E. Cooley	3	Overview by the Moderator
Robert G. Pinco	5	A Legal Perspective on Regulatory Approaches to Switch
Jerome A. Halperin	13	Strategic Issues in the Rx-to-OTC Swtich
William E. Cooley	19	Discussion Panel
Paula Botstein	29	Criteria for Switching New Molecular Entities from Prescription to Over-the-Counter
William E. Gilbertson	33	Criteria For GRAS and GRAE Status for Switch Via the Monograph
Henry A. Palmer	41	OTC Information: Labeling Demands and Beyond
William E. Cooley	45	Question and Answer Session
Jonathan C. Peck	49	Future Health Care Trends Affecting Rx-to-OTC Switch
Stephen W. Schondelmeyer	57	Economic Aspects of Switch
William E. Cooley	67	Question and Answer Session
R. William Soller	73	Welcome and Introduction
Mark Novitch	75	Overview of the Health Professional Panel on Switch
Thomas Q. Garvey III	77	Switch Candidates from the GI Perspective
Leslie Hendeles	83	Switch Candidates from the Pulmonary Perspective

Howard I. Maibach	91	Switch Candidates from the Dermatological Perspective
Norman W. Lavy	95	Switch Candidates from the Internal Medicine Perspective
Mark Novitch	99	Health Professional Panel
Arthur Hull Hayes Jr	111	Overview of the Proceedings: The Future of Switch

Additional Articles

A. C. Cartwright	115	Stereochemistry and Safety, Efficacy and Quality Issues: Genesis of New Regulations
Jeffrey R. Brown	117	Stereochemical Principles
Andrew K. Scott	121	Stereoisomers in Clinical Pharmacology
Charles S. Kumkumian	125	Regulatory Considerations Concerning Stereoisomers in Drug Products
Roger A. Sheldon	129	The Industrial Synthesis of Pure Enantiomers
Akira Kawahara	141	Regulatory Aspects of Biotechnology in Japan
Akira Kawahara	153	Present and Future Aspects of the Japanese Pharmaceutical Affairs Administration
R. Graham Hughes	169	The Management of Third-Party Trials in Europe
Theresa E. Stokes	177	Clinical Data Management – Technology Trends Survey
Vincente Anido Jr **Ashok K. Gumbhir** **Suzan N. Kucukarslan**	189	Comparison of Missouri and Kansas Community Pharmacists' Communication Performance
Georges Lagier **René Jean Royer**	203	Information to the Physician: Role of French Regional Pharmacovigilance Centres
Kenneth I. Kaitin	207	Impact of Policy Research on Drug Development Strategies
Ralph D. Harkins **Renata Albrecht**	213	Design and Analysis of Clinical Trials for Anti-Infective Drug Products
Thomas R. Beam Jr **David N. Gilbert** **Calvin M. Kunin**	225	Updated Guidelines for the Evaluation of New Anti-Infective Drug Products

Louis Lasagna 231 On Achieving Consensus Regarding Fiexible Therapeutic End Points

Robert P. Baker 235 User Survey of an Industry-Based Drug Information Service

Thomas H. Perez 245 Adverse Reaction Reporting Requirements: An Update for Manufacturers

Paul L. Gittelson 251 A Quality Assurance Program for Sponsored Clinical Trials

Karl E. Peace 257 TMO: The Trial Management Organization—A New System for Reducing the Time for Clinical Trials

I Software Survey Section:
PC! info: Time-Oriented Data Management/ Analysis System
Parnassa Regulatory Affairs Document Manager

Volume 24, Number 2 1990

CONTENTS

Statistical Issues in Pharmaceutical Industry: Experimental Design Considerations in Drug Development

John R. Schultz 265 Introduction

David Salsburg 267 Mathematical Modeling and the Design of Studies in Drug Research

Carl M. Metzler
James T. VanderLugt 281 Medical and Statistical Design Issues in Clinical Pharmacology

Lianng Yuh
Stephen J. Ruberg 289 Latin Square Designs in a Comparative Bioavailability Study

H. J. Rostami 299 Experimental Design for Pharmacokinetics Modeling

Donald J. Schuirmann 315 Design of Bioavailability/Bioequivalence Studies

Jonathan B. Skinner 325 Early Exploration of Safety and Efficacy

Nancy L. Geller 341 Design of Phase I and II Trials in Cancer

Walter H. Carter, Jr **Bruce E. Dornseif**	351	Maximizing Drug Benefit in Combination Therapy (Dose-Response Estimation)
Mary F. Johnson	361	Issues in Planning Interim Analyses
H. M. James Hung **Tie-Hua Ng** **George Y. H. Chi** **Raymond J. Lipicky**	371	Response Surface and Factorial Designs for Combination Antihypertensive Drugs
Lilly P. Sanathanan	379	Introduction: Statistical Issues in Animal Safety Studies
Daniel Krewski **Michael Goddard**	381	Principles of Bioassay Design
Patrick J. Wier **John R. Ventre**	395	Statistical Analyses of Reproductive and Developmental Toxicology Studies
Gary G. Koch **Sandra Stinnett** **William A. Sollecito**	407	Summary and Discussion for Experimental Design Considerations in Drug Development
		Additional Articles
Gerald A. Faich **Winifred Castle** **Zbigniew Bankowski** **The CIOMS ADR Working Group**	419	International Adverse Drug Reaction Reporting: The CIOMS Project
Jan Rosier **Paul Demoen**	427	Requirements for Chemical and Pharmaceutical Data in Support of Clinical Trial Applications in the United Kingdom, Canada, the USA, the Nordic Countries, and Australia
	449	Letter to the Editor
	I	Software Survey Section

Volume 24, Number 3 1990

CONTENTS

Michael R. Hamrell	451	FDA Perspective on Computer Assisted Pharmacology/Toxicology Review

Rodney Charles Hall **Paul Isaacson** **Per Sjoberg** **Ture Sjoblom** **Kjell Strandberg** **Olof Tyden**	457	Collaboration Between Australia and Sweden in Drug Regulation
Bette Lee Barton	463	FDA's Inspections of US and Non-US Clinical Studies
Stephen G. Bryant **Seymour Fisher** **David B. Larson** **Nancy J. Olins**	469	Postmarketing Surveillance: Effects of Compensation on Patient Self-Monitoring
Brian L. Strom **Jeffrey L. Carson**	477	Medicaid Billing Data Used to Study the Effects of Marketed Drugs
Uli Hacksell **Lars-Erik Arvidsson** **Anette M. Johansson** **Anders Karlén** **Kristina Luthman** **Stephan Hjorth**	485	Stereoselectivity of Drug Receptor Interactions
Robert E. Pearson **Bill G. Felkey** **J. Tyrone Gibson** **Kenneth N. Barker**	497	Contribution of Computerized Content Analysis to Visualization of *USP DI*
Raymond W. Falk	507	Basic Guidelines for Inference From Clinical Trial Data
Charlotte A. Jankel **John A. McMillan** **Stuart M. Speedie**	513	The Effectiveness of Computerized Drug Interaction Screening Programs in Hospitals
William E. Cwik[1]**o** **B. Tommie Usdin**	531	Standards for CANDAs; Do CALS Standards Point the Way?
Nancy E. Nazari **Yvonne Graham**	537	ICI's Patient Assistance Program
Gregory G. Enas **Nathan H. Enas** **C. Thomas Spradlin** **Michael G. Wilson** **Curtis G. Wiltse**	541	Baseline Comparability in Clinical Trials: Prevention of "Poststudy Anxiety"
L. S. Kaufman **C. S. Snoddy, Jr**	549	Clinical Study Authorizations: Development Strategies

Phn Nelly Baudrihaye	561	Events and Milestones on the Road to 1992 – The Needs of Industry in View of the Internal Market and Evolving Regulatory Procedures
Bjørn Jøldal	569	EFTA/EEC: A Review of Progress in the Harmonization of Regulatory Requirements; Collaboration and Interaction Between Authorities; the PIC and the PER Scheme
Martha M. Meinzinger **William S. Barry**	575	Prospective Study of the Influence of the Media on Reporting Medical Events
Paul Mensinga **Danielle Gabarra**	579	Clinical Quality Assurance: A Method for the Quantification of In-House Audits
Jan Rosier **Paul Demoen**	583	Labeling of Clinical Trial Samples: An Overview of Some Regulatory Requirements
Robert H. Denlinger	591	Industry Perspective on Computer Assisted Toxicology/Pharmacology Review
J. Greg Perkins **Michael Dalton** **George M. Lyon**	597	Utility of Retrovir's® Phase IV Research From a Regulatory Perspective
Charles F. Curran **Osman Bawa**	605	Implementation of a Worldwide Drug Safety Surveillance System
Peter P. Lamy	615	Patient Package Inserts: The Voluntary Approach
Harry Irving Katz **Sheila L. Katz** **Lionel D. Edwards** **John J. Mooney**	621	Survey Results of Remote Data Entry Use by Clinical Investigator Sites
Lionel D. Edwards	629	Multinational Experience Using Remote Data Entry in Clinical Studies
S. Mela	635	European Communities: Outstanding White Paper Proposals for the Completion of Internal Market in the Pharmaceutical Sector
Louis A. Morris **David B. Banks**	639	New Issues in Drug Advertising and Labeling: The Five Advertising End-Runs
	I	Software Survey Section: *Scratchcard Analysis* *BioGraf* *IRB info: Institutional Review Board Data Management System* *Entrypoint 90*

Volume 24, Number 4 1990

CONTENTS

Preclinical Computer and Statistical Applications

Karl E. Peace	647	Introduction
Seth Michelson **Mark Bradshaw** **Chuck Villarrubia** **Bruce Ingraham**	649	PEAS—A Parameter Estimation Analysis System: An In-Laboratory Analysis Tool
Eric M. Chi	659	Analysis of Longitudinal Data by Models with Random Effects and AR(1) Errors
C. Thomas Lin	671	Applications of Partial Least Squares to Spectral Data for Quantitative Determinations of Chemicals in a Mixture
Peter C. Jurs **Richard G. Lawson**	691	Clustering Tendency Applied to Chemical Feature Selection
James W. McFarland **Daniel J. Gans**	705	Cluster Significance Analysis: A New QSAR Tool for Asymmetric Data Sets
Jia-Lin Syi **Rick Gussio** **Jih-Hsiang Chen**	713	Investigation of the Dissociation Process of the Inhibitor Methotrexate from the Methotrexate-Lactobacillus Casei Dihydrofolate Reductase Complex by Using Molecular Dynamics and Semiempirical Molecular Orbital Methods
Mirza W. Ali	727	Exact Versus Asymptotic Tests of Trend of Tumor Prevalence in Tumorigenicity Experiments: A Comparison of *P*-Values for Small Frequency of Tumors
Kem F. Phillips	739	The Statistical Analysis of Data from Bioequivalence Studies Using Stable Isotopes
Lianng Yuh	747	Robust Procedures in Comparative Bioavailability Studies
Shein-Chung Chow	753	Alternative Approaches for Assessing Bioequivalence Regarding Normality Assumptions
		Additional Articles
Rona S. Wasserman	763	Use of an Electronic Publishing System for Production of Pharmaceutical Product Literature

Terry L. Gillum 769 Dictionary Design for Clinical Data Management

Elisabetta Ortelli
Aldo Ferrario 775 Present and Future of a Private Biomedical Database

Alan Gelberg
George D. Armstrong 785 A Study of the Utilization of the FDA's Adverse Drug Reaction Database

Frances O. Kelsey 795 FDA Perspective on IRBs and Overview of FDA Inspection of IRBs

I Software Survey Section:
HASL v. 3.17

V Volume 24 Contents and Author Index